Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Nitrosamine impurities (NDMA/NDEA)

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls.

568 FDA drug recalls with this cause, newest first.

Nitrosamine compounds such as NDMA, NDEA or NMBA are probable human carcinogens that can form during manufacturing or storage. Recalls here trace back to a nitrosamine found above the accepted limit - whether the report names the compound or simply calls it a 'carcinogenic impurity'. It is a newer category, driven by improved testing methods that can now detect impurities that were previously missed, and it is the chemistry behind the large valsartan, losartan and ranitidine (Zantac) recalls.

Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0185-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 63868-480-24 D-0184-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 0363-0131-30 D-0183-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 11673-849-40 D-0179-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0178-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 71713-203-02 D-0177-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 43598-808-62 D-0176-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 30142-131-30 D-0174-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 69842-871-30 D-0173-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 30142-505-34 D-0172-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 49035-404-61 D-0171-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 0363-0010-34 D-0170-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0169-2020